Fairmount Funds Management, Director: Viridian Therapeutics, Inc.\DE VRDN Buy · Filed 25/10/27

Trade details

Type: Insider buy
Amount: $9,999,990
Shares · price: 454,545 sh · $22.00 a share
Held after: 3,914,458 sh
Stock: Viridian Therapeutics, Inc.\DE VRDN
Person: Fairmount Funds ManagementDirector
Trade date: 25/10/23
Filed: 25/10/27
Days to filing: 4 days

First buy in 1 years

Since the last buy: 1.1 years
Last buy: 24/09/13
Insiders buying this week: 3 insiders
Holding change: +13.1%

Viridian Therapeutics, Inc.\DE trades, last 26 weeks

What else happened in Viridian Therapeutics, Inc.\DE around then

Filed or reported within 30 days of the trade day · 25/09/23~25/11/22

Fairmount Funds Management's recent trades

Fairmount Funds ManagementDirector, 10% Stockholder
Planned saleOruka Therapeutics
Planned sale
Oruka Therapeutics
ORKA
$300M
3,553,410 sh
$300M
Filed 07/01
Traded 07/01
Fairmount Funds ManagementDirector
Planned saleSpyre Therapeutics
Planned sale
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
SellSpyre Therapeutics
Sell
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
BuyViridian Therapeutics, Inc.\DE
Buy
Viridian Therapeutics, Inc.\DE
VRDN
$20M
1,176,470 sh
$20M
Filed 05/13
Traded 05/11
Fairmount Funds ManagementDirector
BuyZenas BioPharma
Buy
Zenas BioPharma
ZBIO
$3M
150,000 sh
$3M
Filed 04/01
Traded 03/31

Fairmount Funds Management, Director — bought $10M of Viridian Therapeutics, Inc.\DE VRDN · 454,545 sh @ $22.00 | Whalegun